Coverage of the Science, Innovation and Technology committee session on life sciences investment following Merck’s (MSD in Europe) decision to halt its £1bn UK expansion, from Tuesday 16 September.
Coverage of the Science, Innovation and Technology committee session on life sciences investment following Merck’s (MSD in Europe) decision to halt its £1bn UK expansion, with evidence from MSD’s managing director for UK and Ireland, Ben Lucas, UK president at AstraZeneca, Tom Keith-Roach, Dr Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, health minister Dr Zubir Ahmed and science minister Lord Vallance of Balham, from Tuesday 16 September.
